Table 3.
A) Mean Pharmacokinetic Parameters with ANOVA Analysis of BUP Obtained After Oral Administration of Wellbutrin® SR and Optimized FT to Six Human Volunteers
| A) Mean Pharmacokinetic Parameters | |||||||
|---|---|---|---|---|---|---|---|
| Cmax (ng/mL) | AUC(0–72) (ng.h/mL) | AUC(0-∞) (ng.h/mL) | Kel (1/h) | T1/2 (h) | Tmax | ||
| Wellbutrin® | 10.931 ±2.002 | 226.864 ±79.512 | 297.71 ±131.042 | 0.024 ±0.004 | 30.067 ±7.068 | 3.167 ±0.408 | |
| Optimized FT | 9.116 ±2.821 | 217.15 ±89.31 | 277.957 ±87.451 | 0.023 ±0.007 | 32.707 ±12.852 | 5 ±0 | |
| B) ANOVA table of pharmacokinetic parameters | |||||||
| Statistical test | One-way ANOVA | Independent-samples Kruskal–Wallis test of Tmax | |||||
| Null hypothesis | Ho: The means of parameters are the same for two treatments. The alternative hypothesis here is that two treatments’ means differ |
No difference in the medians of Tmax across categories of treatment. | |||||
| P-value (The significance level is 0.05) | |||||||
| Cmax (ng/mL) | AUC(0–72) (ng.h/mL) | AUC(0-∞) (ng.h/mL) | Kel (1/h) | T1/2 (h) | Tmax | ||
| Optimized FT | Commercial | 0.228 | 0.846 | 0.772 | 0.856 | 0.669 | 0.004 (Reject the null hypothesis) |
Note: Data are presented as mean ±SD (n=6).
Abbreviations: ANOVA, analysis of variance; BUP, bupropion; SR, sustained-release; FT, floating tablet; Cmax, peak plasma concentration; AUC, area under the curve; Kel, elimination rate constant; Tmax, time to reach maximum peak; h, hours; SD, standard deviation.